Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany gives an overview of the current situation for multiple myeloma patients with more advanced disease, i.e. later relapse or exhausted treatment options. In these situations there is an unmet need for drugs which enable a sustained response. The standard treatment at the moment for this population of patients is pomalidomide plus low-dose dexamethasone. In the NIMBUS trial (NCT01311687), highly pre-treated patients with up to 17 prior treatment lines, have shown significant improvement in progression-free survival (PFS) and complete survival. Dr Weisel continues to discuss the recent developments in treatment for multiple myelomas, for example daratumumab and panobinostat, which is a histone deacetylase (HDAC) inhibitor. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Treatment options for patients with advanced multiple myeloma
